- Home
- GENK vs TPST Comparison
GENK vs TPST Comparison
Compare GENK & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | TPST |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 13.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | TPST |
|---|---|---|
| Price | $2.42 | $2.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $5.67 | ★ $12.50 |
| AVG Volume (30 Days) | 66.6K | ★ 75.4K |
| Earning Date | 03-05-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.10 | $2.40 |
| 52 Week High | $7.41 | $13.13 |
Technical Indicators
Market Signals| Indicator | GENK | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 30.56 |
| Support Level | $2.43 | $2.40 |
| Resistance Level | $2.60 | $2.78 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 37.50 | 29.69 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.